Abstract:Objective To analyze differential protein expression of cholangiocarcinoma in peripheral blood by proteomics technology, and to investigate the significance of proteomics technology in early diagnosis of bile duct malignancy. Methods Serum protein from 58 patients with cholangiocarcinoma and 58 controls (20 patients with cholecystolithiasis and 38 healthy people) were detected by surface enhanced laser desorption/ionization-time of flight-mass spectrometry (SELDI-TOF-MS). Ciphergen protein chip software was used to identify proteinic spectra. Results Compared with the spectra of serum protein in control group, there were 10 differentially expressed proteins in bile duct carcinoma group, among which three proteins with relative molecular masses of 5.900×103, 9.080×103 and 11.863×103 were up-regulated (P10-5) and seven proteins with relative molecular masses of 6.959×103, 14.000×103, 14.129×103, 14.302×103, 17.557×103, 17.690×103 and 28.552×103 were down-regulated (P10-5). The average concentration of protein with the relative molecular mass of 11.863×103 in cholangiocarcinoma group was eight times more than that in controls group. At the stage Ⅱ of cholangiocarcinoma, the expression of protein point with a relative molecular mass of 5.900×103 was significantly higher than those patients at the stage Ⅲ and stage Ⅳ (P10-5); while there were no statistical difference of expression between differ-ent clinical stages for the other 9 proteins points. And there were no significant expression differences of the above 10 proteins between the patients with and without jaundice following cholangiocarcinoma. Instead, another three proteins with relative molecular masses of 7.255×103, 12.364×103 and 15.873×103 were detected to have different protein expressions. And all of them showed high expressions in jaundice group (P10-5). Conclusion There are remarkable differences of the expressions of serum proteins in peripheral blood in patients with cholangiocarcinoma. The protein point with a relative molecular mass of 11.863×103 may be a potential biomarker for early diagnosis of cholangiocarcinoma.

Antibody array-based proteomic screening of novel biomarkers in malignant biliary stricture

A Comparative Proteomic Analysis of Bile for Biomarkers of Cholangiocarcinoma

Comparative Proteomic Profiling Of Human Bile Reveals Ssp411 As A Novel Biomarker Of Cholangiocarcinoma

Analysis of Differentially Expressed Genes in Malignant Biliary Strictures

Detection of Tumor Markers in the Bile for Differential Diagnosis of Benign and Malignant Biliary Tract Stricture

A Prospective Proteomic-Based Study for Identifying Potential Biomarkers for the Diagnosis of Cholangiocarcinoma

Identification of hepatocellular-carcinoma-associated antigens and autoantibodies by serological proteome analysis combined with protein microarray.

Proteome analysis and tissue microarray for profiling protein markers associated with lymph node metastasis in colorectal cancer.

Proteomics analysis and evaluation of biomarkers for detection of cholangiocarcinoma

The role of bile acid subtypes in the diagnosis of cholangiocarcinoma

Proteomic-Based Analysis for Identification of Potential Serum Biomarkers in Gallbladder Cancer

Detection of Differential Expression of Serum Protein in Peripheral Blood by SELDI-TOF-MS Technology in Cholangiocarcinoma

A machine learning-based predictive model for biliary stricture attributable to malignant tumors: a dual-center retrospective study

LCN 1 is highly expressed in cholangiocarcinoma patients and indicates poor prognosis

Implementing Massive Parallel Sequencing into Biliary Samples Obtained through Endoscopic Retrograde Cholangiopancreatography for Diagnosing Malignant Bile Duct Strictures

Identification of Bile Biomarkers of Biliary Tract Cancer Through A Liquid Chromatography/Mass Spectrometry-Based Metabolomic Method

Proteomic Identification of Tumor Biomarkers Associated with Primary Gallbladder Cancer

Itraq-2dlc-Esi-Ms/Ms Based Identification of A New Set of Immunohistochemical Biomarkers for Classification of Dysplastic Nodules and Small Hepatocellular Carcinoma

Detection and analysis of biliary glycoprotein glycan structure changes in differential diagnosis of benign and malignant biliary disease

Bile Metabolic Fingerprints Distinguish Biliary Tract Cancer from Benign Biliary Diseases

Identification of differentially expressed biliary proteins induced by cholangiocarcinoma using 2D-DIGE